L-rhamnose antigen: a promising alternative to α-gal for cancer immunotherapies.
The targeting of autologous vaccines toward antigen presenting cells (APCs) via the in vivo complexation between anti α-Gal (anti-Gal) antibodies and α-Gal antigens presents a promising cancer immunotherapy with enhanced immunogenicity. This strategy takes advantage of the ubiquitous anti-Gal antibody in human serum. In contrast to the α-Gal epitope, the recent identification of high titers of anti-l-rhamnose (anti-Rha) antibodies in humans reveals a new approach toward immunotherapy employing l-rhamnose (Rha) monosaccharides. In order to evaluate this simple antigen in preclinical applications, we have synthesized Rha-conjugated immunogens and successfully induced high titers of anti-Rha antibodies in wildtype mice. Moreover, our studies demonstrate for the first time that wildtype mice could replace α1,3galactosyltransferase knockout (α1,3GT KO) mice in such antigen/antibody-mediated vaccine design when developing cancer immunotherapies.
The Department of Chemistry and Biochemistry, The Ohio State University, 484 West 12th Avenue, Columbus, Ohio 43210, United States.
Wenlan
W
Chen
Li
L
Gu
Wenpeng
W
Zhang
Edwin
E
Motari
Li
L
Cai
Thomas J
TJ
Styslinger
Peng George
PG
Wang
D000818:Animals; D000906:Antibodies / Q000276:immunology / Q000378:metabolism; D000939:Epitopes / Q000276:immunology* / Q000378:metabolism; D005690:Galactose / Q000276:immunology* / Q000378:metabolism; D005700:Galactosyltransferases / Q000378:metabolism; D006801:Humans; D007167:Immunotherapy / Q000379:methods*; D051379:Mice; D018345:Mice, Knockout; D008954:Models, Biological; D009369:Neoplasms / Q000276:immunology / Q000628:therapy*; D012210:Rhamnose / Q000276:immunology* / Q000378:metabolism; D014612:Vaccines / Q000276:immunology / Q000378:metabolism
D000906:Antibodies; D000939:Epitopes; D014612:Vaccines; D005700:Galactosyltransferases; D012210:Rhamnose; D005690:Galactose